Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

1.

Dose reduction effective in alleviating symptoms of saquinavir toxicity.

Stephan C, Carlebach A, Rottmann C, Haberl A, Dauer B, von Hentig N, Kurowski M, Staszewski S.

Int J STD AIDS. 2007 Feb;18(2):81-4.

PMID:
17331276
[PubMed - indexed for MEDLINE]
2.

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.

von Hentig N, Müller A, Rottmann C, Wolf T, Lutz T, Klauke S, Kurowski M, Oertel B, Dauer B, Harder S, Staszewski S.

Antimicrob Agents Chemother. 2007 Apr;51(4):1431-9. Epub 2007 Feb 12.

PMID:
17296738
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.

von Hentig N, Müller A, Rottmann C, Lutz T, Klauke S, Kurowski M, Staszewski S, Harder S.

Eur J Med Res. 2006 Jun 30;11(6):236-44.

PMID:
16820336
[PubMed - indexed for MEDLINE]
4.

Mega-HAART: preliminary results and correlation with baseline resistance.

Rottmann C, Miller V, Staszewski S.

Antivir Ther. 1999;4 Suppl 3:93-4.

PMID:
16021879
[PubMed - indexed for MEDLINE]
5.

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.

Bickel M, Stephan C, Rottmann C, Carlebach A, Haberl A, Kurowski M, Staszewski S.

Scand J Infect Dis. 2005;37(6-7):520-2.

PMID:
16012018
[PubMed - indexed for MEDLINE]
6.

The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.

Bickel M, Rickerts V, Stephan C, Jacobi V, Rottmann C, Dauer B, Carlebach A, Thalhammer A, Miller V, Staszweski S.

HIV Med. 2005 May;6(3):179-84.

PMID:
15876284
[PubMed - indexed for MEDLINE]
7.

[Clinical presentation and management of the severe acute respiratory syndrome (SARS)].

Rickerts V, Wolf T, Rottmann C, Preiser W, Drosten C, Jakobi V, Leong HN, Brodt HR.

Dtsch Med Wochenschr. 2003 May 16;128(20):1109-14. German.

PMID:
12748900
[PubMed - indexed for MEDLINE]
8.

A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.

Staszewski S, Haberl A, Carlebach A, Rottmann C, Miller V, Gute P.

HIV Med. 2000 Jul;1(3):162-3. No abstract available.

PMID:
11737345
[PubMed - indexed for MEDLINE]
9.

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.

Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S.

AIDS. 2000 Sep 29;14(14):2129-36.

PMID:
11061654
[PubMed - indexed for MEDLINE]
10.

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.

Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Lepri AC, Phillips AN.

J Infect Dis. 1999 Aug;180(2):530-3.

PMID:
10395876
[PubMed - indexed for MEDLINE]
Free Article
11.

Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.

Miller V, Phillips A, Rottmann C, Staszewski S, Pauwels R, Hertogs K, de Béthune MP, Kemp SD, Bloor S, Harrigan PR, Larder BA.

J Infect Dis. 1998 Jun;177(6):1521-32.

PMID:
9607829
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk